The ability to form biofilm influences Mycobacterium avium invasion and translocation of bronchial epithelial cells

被引:91
作者
Yamazaki, Y
Danelishvili, L
Wu, M
Hidaka, E
Katsuyama, T
Stang, B
Petrofsky, M
Bildfell, R
Bermudez, LE [1 ]
机构
[1] Oregon State Univ, Coll Vet Med, Dept Biomed Sci, Corvallis, OR 97331 USA
[2] Oregon State Univ, Coll Sci, Dept Microbiol, Corvallis, OR 97331 USA
[3] Sinshu Univ, Sch Med, Dept Lab Med, Matsumoto, Nagano 3908621, Japan
[4] Calif Pacific Med Ctr, Res Inst, Kuzell Inst, San Francisco, CA USA
关键词
D O I
10.1111/j.1462-5822.2005.00667.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Organisms of the Mycobacterium avium complex (MAC) are widely distributed in the environment, form biofilms in water pipes and potable water tanks, and cause chronic lung infections in patients with chronic obstructive pulmonary disease and cystic fibrosis. Pathological studies in patients with pulmonary MAC infection revealed granulomatous inflammation around bronchi and bronchioles. BEAS-2B human bronchial epithelial cell line was used to study MAC invasion. MAC strain A5 entered polarized BEAS-2B cells with an efficiency of 0.1 +/- 0.03% in 2 h and 11.3 +/- 4.0% in 24 h. In contrast, biofilm-deficient transposon mutants 5G4, 6H9 and 9B5 showed impaired invasion. Bacteria exposed to BEAS-2B cells for 24 h had greater ability to invade BEAS-2B cells compared with bacteria incubated in broth. M. avium had no impact on the monolayer transmembrane resistance. Scanning electron microscopy showed that MAC A5 forms aggregates on the surface of BEAS-2B cell monolayers, and transmission electron microscopy evidenced MAC within vacuoles in BEAS-2B cells. Cells infected with the 5G4 mutant, however, showed significantly fewer bacteria and no aggregates on the cell surface. Mutants had impaired ability to cause infection in mice, as well. The ability to form biofilm appeared to be associated with the invasiveness of MAC A5.
引用
收藏
页码:806 / 814
页数:9
相关论文
共 29 条
[1]   CHARACTERIZATION OF FIBRONECTIN-BINDING ANTIGENS RELEASED BY MYCOBACTERIUM-TUBERCULOSIS AND MYCOBACTERIUM-BOVIS BCG [J].
ABOUZEID, C ;
RATLIFF, TL ;
WIKER, HG ;
HARBOE, M ;
BENNEDSEN, J ;
ROOK, GAW .
INFECTION AND IMMUNITY, 1988, 56 (12) :3046-3051
[2]   Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease [J].
Aksamit, TR .
CLINICS IN CHEST MEDICINE, 2002, 23 (03) :643-+
[3]   MYCOBACTERIUM-AVIUM COMPLEX INFECTION AND AIDS - ADVANCES IN THEORY AND PRACTICE [J].
BENSON, CA ;
ELLNER, JJ .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (01) :7-20
[4]   Host defense against Mycobacterium avium does not have an absolute requirement for major histocompatibility complex class I-restricted T cells [J].
Bermudez, LE ;
Petrofsky, M .
INFECTION AND IMMUNITY, 1999, 67 (06) :3108-3111
[5]   FACTORS AFFECTING INVASION OF HT-29 AND HEP-2 EPITHELIAL-CELLS BY ORGANISMS OF THE MYCOBACTERIUM-AVIUM COMPLEX [J].
BERMUDEZ, LE ;
YOUNG, LS .
INFECTION AND IMMUNITY, 1994, 62 (05) :2021-2026
[6]   The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells [J].
Bermudez, LE ;
Sangari, FJ ;
Kolonoski, P ;
Petrofsky, M ;
Goodman, J .
INFECTION AND IMMUNITY, 2002, 70 (01) :140-146
[7]   A subinhibitory concentration of clarithromycin inhibits Mycobactetium avium biofilm formation [J].
Carter, G ;
Young, LS ;
Bermudez, LE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (12) :4907-4910
[8]   Characterization of biofilm formation by clinical isolates of Mycobacterium avium [J].
Carter, G ;
Wu, M ;
Drummond, DC ;
Bermudez, LE .
JOURNAL OF MEDICAL MICROBIOLOGY, 2003, 52 (09) :747-752
[9]  
COOPER AM, 1998, FRONT BIOSCI, V3, P141
[10]  
DAM T, 2006, IN PRESS J INFECT DI